

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023489 A3

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2022/074981
- (22) **International Filing Date:**
15 August 2022 (15.08.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/234,226 17 August 2021 (17.08.2021) US
63/329,138 08 April 2022 (08.04.2022) US

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

- (88) **Date of publication of the international search report:**
30 March 2023 (30.03.2023)

- (71) **Applicants:** **HEMOGENYX PHARMACEUTICALS LLC** [US/US]; 760 Parkside Avenue, Ste 212, Brooklyn, New York 11226 (US). **ELI LILLY AND COMPANY** [US/US]; P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

- (72) **Inventors:** **SANDLER, Vladislav M.**; 142 West End Avenue, Apt 3P, New York, New York 10023 (US). **SHRESTHA, Elina**; 41-34 Crescent Street, Apt 3H, Long Island City, New York 11101 (US). **SIROCHINSKY, Carina Rachel**; 504 W 164th Street, Apt B2, New York, New York 10032 (US). **LIANG, Raymond**; 519 Borden Avenue, Apt 8J, Long Island City, New York 11101 (US). **BEN JEHUDA, Ronen**; 35 Park Avenue, Apt 2H, New York, New York 10016 (US). **KORYTKO, Andrew Ihor**; 4720 Marblehead Bay Drive, Oceanside, California 92057 (US). **SKORA, Andrew Dixon**; 429 S. Sierra Avenue, Unit 138, Solana Beach, California 92075 (US). **ADER, Max Ephraim**; 13565 Millpond Way, San Diego, California 92129 (US). **CHILTON, Todd Christopher**; 11005 Caminito Arcada, San Diego, California 92131 (US).

- (74) **Agent:** **ELBERT, Maya et al.**; 1299 Pennsylvania Ave., NW Suite 700, Washington, District of Columbia 20004 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** BISPECIFIC ANTI-FLT3/CD3 ANTIBODIES AND METHODS OF USE

(57) **Abstract:** Provided herein are bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, such as the antibodies and fragments that specifically bind human FLT3 and human CD3. In some aspects, provided herein are optimized humanized, bispecific anti-FLT3/CD3 antibodies and antigen binding fragments thereof, optionally, having certain amino acid substitutions that confer advantageous properties (e.g., optimal antigen binding, manufacturability and/or half-life properties). Also provided herein are pharmaceutical compositions comprising such antibodies or fragments. Also provided herein are methods of use of such antibodies and fragments.



WO 2023/023489 A3